Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Autolus Therapeutics ( (AUTL) ) has shared an announcement.
On May 14, 2026, Autolus Therapeutics reported first-quarter 2026 results showing net product revenue of $26.2 million from AUCATZYL, up sharply from $9 million a year earlier, and a first-time positive gross margin in its acute lymphoblastic leukemia business, supported by strong launches in the U.S. and the U.K. While the company remained loss-making with a net loss of $71.6 million and cash of $229.4 million at March 31, it reiterated its 2026 revenue outlook for AUCATZYL of $120 million to $135 million and said existing liquidity should fund operations into the fourth quarter of 2027.
Autolus highlighted ongoing clinical progress, including pivotal Phase 2 trials of obe-cel in pediatric relapsed or refractory B-ALL and lupus nephritis and early-stage studies in progressive MS and light-chain amyloidosis, as it seeks to broaden the drug’s indications. In April 2026 the company launched a restructuring and cost-reduction initiative, including a 13% workforce cut and expected $15 million in annualized savings from 2027, aiming to improve gross margins, support scalable growth and accelerate the path to profitability for its ALL franchise.
The most recent analyst rating on (AUTL) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Autolus Therapeutics stock, see the AUTL Stock Forecast page.
Spark’s Take on AUTL Stock
According to Spark, TipRanks’ AI Analyst, AUTL is a Neutral.
The score is held down primarily by weak financial performance (large losses, negative gross profit, and rising cash burn with a shrinking equity cushion). Offsetting this is a relatively constructive earnings outlook with reiterated 2026 revenue guidance and expected positive gross margins, while technicals remain weak-to-neutral and valuation is difficult to assess meaningfully due to negative earnings and no dividend support.
To see Spark’s full report on AUTL stock, click here.
More about Autolus Therapeutics
Autolus Therapeutics plc, listed on Nasdaq as AUTL, is a commercial-stage biopharmaceutical company focused on developing, manufacturing and delivering next-generation programmed T cell therapies. Its lead product AUCATZYL (obe-cel) targets acute lymphoblastic leukemia, with commercial launches in the U.S. and U.K., while its pipeline extends into pediatric leukemia, lupus nephritis, progressive multiple sclerosis and light-chain amyloidosis.
Average Trading Volume: 1,625,935
Technical Sentiment Signal: Hold
Current Market Cap: $425.8M
See more data about AUTL stock on TipRanks’ Stock Analysis page.